Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
153 hedge funds and large institutions have $1.68B invested in Akero Therapeutics in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 60 increasing their positions, 53 reducing their positions, and 34 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
13% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 53
2.19% less ownership
Funds ownership: 106.04% → 103.85% (-2.2%)
9% less capital invested
Capital invested by funds: $1.85B → $1.68B (-$162M)
12% less funds holding
Funds holding: 173 → 153 (-20)
23% less call options, than puts
Call options by funds: $5.99M | Put options by funds: $7.75M
50% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$23.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$16.1M |
| 3 |
BlackRock
New York
|
+$14.8M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$14.2M |
| 5 |
Morgan Stanley
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$34.6M |
| 2 |
FAM
Fred Alger Management
New York
|
-$25.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$23.7M |
| 4 |
Millennium Management
New York
|
-$13.3M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$7.68M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Los Angeles Capital Management
Los Angeles,
California
| – | -$211K | -8,343 | Closed |
|
177
Nomura Holdings
Tokyo,
Japan
| – | -$203K | -8,046 | Closed |
|
178
Squarepoint
New York
| – | -$202K | -7,997 | Closed |
|
|
CSS
179
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$180K | -7,119 | Closed |
|
|
MLICM
180
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$81.9K | -3,242 | Closed |
|
181
Group One Trading
Chicago,
Illinois
| – | -$51.7K | -2,416 | Closed |
|
182
KBC Group
Brussels,
Belgium
| – | -$38K | -1,521 | Closed |
|
|
QT
183
Quantbot Technologies
New York
| – | -$27.8K | -1,100 | Closed |
|
|
IGWM
184
ICA Group Wealth Management
Denver,
Colorado
| – | -$2.78K | -110 | Closed |
|
|
RAM
185
Riggs Asset Management
Dallas,
Pennsylvania
| – | -$354 | -14 | Closed |
|
|
AWM
186
Avior Wealth Management
Omaha,
Nebraska
| – | -$303 | -12 | Closed |
|
AKRO Hedge Fund Activity: Q2 2024 in Review
153 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2024, worth a combined $1.68B — down 8.8% from $1.85B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of AKRO and 17 opened new positions — a net loss of 17 holders — while 53 trimmed existing stakes and 60 added.
The largest buyer was Braidwell, opening a new position worth an estimated $23.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $34.6M.
- 153 institutional investors held Akero Therapeutics (AKRO) as of Q2 2024, down from 173 in Q1 2024.
- Funds reported $1.68B of Akero Therapeutics stock for Q2 2024, down 8.8% quarter-over-quarter.
- 17 funds opened new Akero Therapeutics positions in Q2 2024 and 34 closed out, a net change of -17 holders.
- The largest Akero Therapeutics buyer in Q2 2024 was Braidwell, an estimated $23.2M added.
- The largest Akero Therapeutics seller in Q2 2024 was Baker Bros. Advisors, an estimated $34.6M sold.
Based on aggregated 13F filings for Q2 2024.